A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS)
Phase 1
- Registration Number
- CTIS2023-506827-26-00
- Lead Sponsor
- ovo Nordisk A/S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1467
Inclusion Criteria
Male or female, age =18 years at the time of signing informed consent, Diagnosed with type 2 diabetes mellitus., HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).
Exclusion Criteria
NA
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method